| Pharmaceutical Information |
| Drug Name |
Abatacept |
| Drug ID |
BADD_D00012 |
| Description |
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). |
| Indications and Usage |
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis.[L20504] In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.[L20504]
Abatacept is also indicated for the prophylaxis of acute graft-versus-host disease, in combination with [methotrexate] and a calcineurin inhibitor such as [tacrolimus], in patients two years of age and older who are undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.[L20504] |
| Marketing Status |
approved |
| ATC Code |
L04AA24 |
| DrugBank ID |
DB01281
|
| KEGG ID |
D03203
|
| MeSH ID |
D000069594
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0EW4L
|
| NDC Product Code |
0003-2814; 0003-2818; 70409-2187; 0003-2188; 0003-2187 |
| UNII |
7D0YB67S97
|
| Synonyms |
Abatacept | CTLA-4-Ig | Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin | Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin | CTLA4-Ig | CTLA4-Ig Immunoconjugate | CTLA4 Ig Immunoconjugate | Immunoconjugate, CTLA4-Ig | CTLA4-Fc | BMS224818 | BMS-224818 | BMS 224818 | Belatacept | Orencia | BMS 188667 | BMS-188667 | BMS188667 | LEA29Y | Nulojix |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
332348-12-6 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
